713. Summary of Comparative Ceftaroline Activity against Major Bacterial Pathogens in Russia: Results of Multicenter Study
Session: Poster Abstract Session: Antimicrobials: Novel Agents
Friday, October 4, 2013
Room: The Moscone Center: Poster Hall C
Background: Ceftaroline is a new broad-spectrum cephalosporin with enhanced activity against Gram-positive pathogens, including MRSA. The objective of the study was to determine in vitro activity of ceftaroline and other clinically available antimicrobials against major bacterial pathogens from different regions of Russian Federation.

Methods:  A total of 1993 resent consecutive, non-duplicate isolates from 27 centers in geographically distant parts of Russia were included in the study. Susceptibility testing was performed by serial double dilution method with the interpretation of results according to CLSI recommendations (CLSI M100-S23). Among tested strains 632 were S. aureus (SA, 278-MRSA), 706 - S. pneumoniae (SP), 340 – beta-hemolytic streptococci (STR), 230 – Enterobacteriaceae (EB, all-ESBL-negative), 85 – H. influenzae (HI).

Results:  Overall susceptibility rates to ceftaroline were 90.4% for SA (100% for MSSA, 78.1% for MRSA), 100% for SP and STR, 91.3 for EB, and 98.8 – for HI. MIC90 and susceptibility rates for ceftaroline and other antimicrobials are shown in the table.

 

SA

SP

STR

HI

EB

Drug

MIC90
(mg/l)

S
(%)

MIC90
(mg/l)

S
(%)

MIC90
(mg/l)

S
(%)

MIC90
(mg/l)

S
(%)

MIC90
(mg/l)

S
(%)

Amikacin

 

 

 

 

4

100

Amoxicillin

 

0.125

98.6

0.06

100

32

88.2

256

54.4

Amox./clav.

 

 

 

1

98.8

32

72.6

Azithromycin

 

 

 

2

100

 

 

Cefotaxime

 

 

 

0.015

100

0.125

100

Ceftaroline

1

90.4

0.03

100

0.004

100

0.5

98.8

0.5

91.3

Ceftriaxone

 

0.25

97.3

 

 

 

 

Ciprofloxacin

64

52.9

 

 

0.015

100

16

84.4

Clindamycin

512

73.3

0.06

93.2

0.03

99.1

 

 

 

Co-trimoxazole

0.25

98.7

 

 

16

68.2

128

80.9

Erithromycin

512

62.8

0.25

90.8

0.25

91.5

 

 

 

Ertapenem

 

 

 

 

0.06

100

Gentamicin

128

62.2

 

 

 

2

94.4

Levofloxacin

 

1

100

1

100

 

 

Linezolid

2

100

0.5

100

1

100

 

 

Oxacillin

256

56

 

 

 

 

Vancomycin

1

100

 

05

100

 

 

Tetracycline

64

69.2

16

66.9

32

47.1

0.5

97.7

 

Conclusion:  Ceftaroline exhibited high potency against variety of major Gram-positive and Gram-negative pathogens, including MRSA, in this large selection of geographically and temporally diverse collection of isolates.

Roman Kozlov, MD, MSc, PhD1, Marina Sukhorukova, MD, PhD2, Mikhail Edelstein, PhD3 and Andrey Dekhnich, MD, MSc, PhD4, (1)Institute of Antimicrobial Chemotherapy, Smolensk, Russia, (2)Smolensk State Medical Academy, Smolensk, Russia, (3)Inst. of Antimicrobial Chemotherapy, Smolensk, Russian Federation, (4)Smolensk State Medical Academy, Smolensk, Russian Federation

Disclosures:

R. Kozlov, None

M. Sukhorukova, None

M. Edelstein, None

A. Dekhnich, None

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.